Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/SYROS PHARMACEUTICALS INC/ 15-12G

SEC Filing · 15-12G

SYROS PHARMACEUTICALS INC

SYRSOTCEQUITYCurrent

SEC Filing

Filed Mar 20, 2025Accepted Mar 20, 2025, 1:01 PM EDTCIK 1556263Accession 0001193125-25-059362
View company →Permanent SEC source ↗
Share

Company context

Syros’ mission was to develop new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros had developed tamibarotene, an oral selective RARα agonist, in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.

Current securities

SYRSOTC · EQUITY · Current
Historical securities (3)
SYRSNASDAQ · EQUITY · Historical · closed Mar 19, 2025SYRSOTC · EQUITY · Historical · closed Oct 11, 2022SYRSWOTC · WARRANT · Historical · closed Oct 11, 2022

Recent company filings

  1. SCHEDULE 13D/A - filed by Samsara BioCapital, L.P. regarding Syros Pharmaceuticals, Inc.Mar 27, 2025
  2. EFFECT filingMar 11, 2025
  3. EFFECT filingMar 11, 2025
  4. EFFECT filingMar 11, 2025
  5. EFFECT filingMar 11, 2025

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.